DDX53 and neoplasm: Tolba and co-workers further extended cytokine-based HSV-1 amplicon vaccination therapy by delivering another potent chemokine, secondary lymphoid tissue chemokine (SLC), alone, or in combination with a co-stimulatory ligand (e.g. CD40L) via HSV-1 amplicons in murine models of B cell lymphoma (A20) and adenocarcinoma (CT-26) to enhance tumor-specific APC recruitment and maturation in lymph nodes for the elicitation of a T-cell-mediated anti-tumor responses [123].